Jazz Pharmaceuticals plc (J7Z.F)
| Previous close | 99.96 |
| Open | 100.25 |
| Bid | 100.95 x 1700 |
| Ask | 102.40 x 1700 |
| Day's range | 100.25 - 100.25 |
| 52-week range | 99.76 - 134.35 |
| Volume | |
| Avg. volume | 8 |
| Market cap | 6.278B |
| Beta (5Y monthly) | 0.61 |
| PE ratio (TTM) | 17.59 |
| EPS (TTM) | 5.70 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 208.50 |
ZacksArdelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PR NewswireJazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present or publish eight abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2024 in Chicago. Presentations include data from trials of zanidatamab, Zepzelca® (lurbinectedin), and Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn). A poster featuring the study design for the JZP898 Phase 1 trial in progress will also be presented.
ZacksJazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
